CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 278.11 AUD 0.31% Market Closed
Market Cap: 134.7B AUD
Have any thoughts about
CSL Ltd?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

19.7
Current
23.1
Median
4.2
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
19.7
=
Enterprise Value
149.7B AUD
/
EBITDA
4.8B USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBITDA: 16.2
19.7
42%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16.1
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.8
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -220.7 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
17.2
2-Years Forward
EV/EBITDA
15.4
3-Years Forward
EV/EBITDA
13.9

See Also

Discover More